Atlas Trials

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Clinical trial NCT04283006 · RECRUITING

Trial details

NCT number
NCT04283006
Sponsor
He Huang
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed and RefractoryLymphoid Hematological Malignancies
Start date
2018-05-23
Primary completion
2023-05-23
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.